On this page
NDUFV1
NADH:ubiquinone oxidoreductase core subunit V1
NDUFV1 is located on the long (q) arm of chromosome 11, at band 11q13.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 11 in the library →Available at Jeen Health
Clinical tests that include this
Overview
NDUFV1 encodes NADH:ubiquinone oxidoreductase core subunit V1, a critical component of mitochondrial respiratory chain complex I. This complex is the entry point for electrons into the oxidative phosphorylation pathway, the process by which cells generate most of their adenosine triphosphate (ATP) energy currency. The NDUFV1 protein contains the flavin mononucleotide (FMN) binding site required for accepting electrons from NADH, making it indispensable for complex I catalytic activity.
Pathogenic variants in NDUFV1 result in complex I deficiency, one of the most common causes of mitochondrial respiratory chain disorders. Because complex I dysfunction impairs ATP synthesis, tissues with high energy demands such as the brain, heart, and skeletal muscle are typically most affected. NDUFV1-related disorders are inherited in an autosomal recessive manner, meaning that individuals require two altered copies of the gene to develop the condition.
What the gene does
The NDUFV1 protein is a core catalytic subunit of NADH:ubiquinone oxidoreductase, also known as complex I or NADH dehydrogenase. This large multi-protein assembly is embedded in the inner mitochondrial membrane and catalyses the first step of the electron transport chain. NDUFV1 specifically binds FMN, a cofactor that accepts electrons from NADH generated during glycolysis and the citric acid cycle. These electrons are then transferred through a series of iron-sulphur clusters to ubiquinone (coenzyme Q), reducing it to ubiquinol.
This electron transfer is coupled to the pumping of protons across the inner mitochondrial membrane, establishing the electrochemical gradient that drives ATP synthase. Complex I contributes approximately 40 percent of the proton-motive force used for ATP production through oxidative phosphorylation. NDUFV1 is essential for maintaining the structural integrity and catalytic efficiency of the entire complex I assembly. Without functional NDUFV1, complex I cannot efficiently oxidise NADH, leading to impaired cellular respiration and reduced ATP generation, particularly detrimental to organs with high metabolic demands.
Video: Genetics 101
Chromosome location
NDUFV1 is located on the long arm of chromosome 11 at position 13.2 (11q13.2). The genomic region spans multiple exons that encode the 464-amino-acid protein. This chromosomal location is shared with several other genes, but NDUFV1 occupies a discrete locus within this band.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The NDUFV1 protein comprises 464 amino acids and forms part of the flavoprotein fraction of complex I. The protein contains a binding site for FMN, the prosthetic group essential for electron acceptance from NADH. Structural studies of complex I indicate that NDUFV1 is positioned within the peripheral arm of the complex, which extends into the mitochondrial matrix where NADH oxidation occurs.
Key variants
Pathogenic variants in NDUFV1 are predominantly loss-of-function changes that impair the protein's catalytic activity or destabilise complex I assembly. Missense variants affecting the FMN-binding region or iron-sulphur cluster coordination sites are commonly reported. Nonsense and frameshift variants that result in truncated or absent protein are also pathogenic. The spectrum of clinical severity associated with NDUFV1 variants is broad, likely reflecting residual complex I activity levels.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.153G>A | p.Trp51Ter | Pathogenic | ★★☆☆ | Inborn genetic diseases |
c.296G>A | p.Trp99Ter | Pathogenic/Likely pathogenic | ★★☆☆ | NDUFV1-related disorder |
c.365C>T | p.Pro122Leu | Pathogenic/Likely pathogenic | ★★☆☆ | Mitochondrial complex I deficiency, nuclear type 4 |
c.419_420insTCCTCACAAGCTGA | p.Glu140fs | Pathogenic/Likely pathogenic | ★★☆☆ | Mitochondrial complex I deficiency, nuclear type 4 |
c.475C>T | p.Arg159Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 5 |
c.520C>T | p.Arg174Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Mitochondrial complex I deficiency, nuclear type 4 |
c.53_54del | p.Val18fs | Pathogenic | ★★☆☆ | not provided |
c.611A>G | p.Tyr204Cys | Pathogenic/Likely pathogenic | ★★☆☆ | Mitochondrial complex I deficiency, nuclear type 4 |
c.684dup | p.Phe229fs | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.753_756del | p.Pro252fs | Pathogenic | ★★☆☆ | Leigh syndrome |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
NDUFV1-related mitochondrial disorders encompass a range of phenotypes unified by complex I deficiency. Affected individuals often present with neurological features including developmental delay, intellectual disability, seizures, and movement disorders such as dystonia or chorea. Leigh syndrome, a severe progressive neurodegenerative disorder typically beginning in infancy, is among the recognised presentations. Other manifestations may include leukoencephalopathy (white matter abnormalities on brain imaging), basal ganglia involvement, and metabolic derangements. The age of onset and severity vary considerably, with some individuals experiencing neonatal-onset disease and others presenting later in childhood.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic NDUFV1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
NDUFV1 holds green (high confidence) status across multiple NHS Genomic Medicine Service gene panels. These include the Mitochondrial disorders panel, Mitochondrial disorder with complex I deficiency panel, and the Likely inborn error of metabolism panel. The gene is also included in panels for Intellectual disability, Early onset or syndromic epilepsy, Childhood onset dystonia, chorea or related movement disorder, and Inherited white matter disorders, reflecting the broad phenotypic spectrum associated with pathogenic variants. Green classification indicates strong evidence supporting the gene-disease relationship and its relevance for clinical diagnostic testing within the NHS.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What inheritance pattern is associated with NDUFV1-related conditions?
NDUFV1-related disorders follow an autosomal recessive inheritance pattern. This means an individual must inherit two pathogenic variants, one from each parent, to develop the condition. Parents who each carry one variant are typically unaffected carriers.
Why are neurological symptoms common in NDUFV1-related disorders?
The brain has exceptionally high energy demands and relies heavily on mitochondrial ATP production. When NDUFV1 variants impair complex I function, the resulting energy deficit disproportionately affects the central nervous system, leading to developmental delay, seizures, movement disorders, and progressive neurodegeneration.
Can NDUFV1 variants cause symptoms that begin in adulthood?
The majority of NDUFV1-related presentations occur in infancy or early childhood. However, the clinical spectrum is variable, and some individuals with milder variants may experience later onset of symptoms, though this is less common.